FDA Inspection 611945 — Celgene Corporation
The FDA completed an inspection of Celgene Corporation on Sep 3, 2009 in Summit, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 6 citations were issued during this inspection. Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Sep 3, 2009
- Fiscal Year
- 2009
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Summit, NJ (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)
Citations
| ID | CFR | Description |
|---|---|---|
| 6728 | 21 CFR 314.80(b) | Failure to review ADE information |
| 6730 | 21 CFR 314.80(b) | Failure to develop written procedures |
| 6732 | 21 CFR 314.80(c)(1)(i) | Late submission of 15-day report |
| 6737 | 21 CFR 314.80(c)(1)(ii) | Failure to separately submit original and follow-up reports |
| 6829 | 21 CFR 314.80(c)(2) | Failure to report non-alert ADEs |
| 6831 | 21 CFR 314.80(c)(2) | Late submission of quarterly safety reports |